Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions

Advances in Enzyme Regulation

Volumn 51, Issue 1, 2011, Pages 106-116

  Gratacap, Marie Pierre ^a   Guillermet Guibert, Julie ^a   Martin, Valérie ^a   Chicanne, Gaëtan ^a   Tronchère, Hélène ^a   Gaits Iacovoni, Frédérique ^a   Payrastre, Bernard ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79954545891     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2010.09.011     Document Type: Review

References (68)

1. Al-Qassab H., Smith M.A., Irvine E.E., Guillermet-Guibert J., Claret M., Choudhury A.I., et al. Dominant role of the p110beta isoform of PI3K over p110alpha in energy homeostasis regulation by POMC and AgRP neurons. Cell Metab 2009, 10:343-354.
2. Bi L., Okabe I., Bernard D.J., Nussbaum R.L. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002, 13:169-172.
3. Blero D., Payrastre B., Schurmans S., Erneux C. Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch 2007, 455:31-44.
4. Canobbio I., Stefanini L., Cipolla L., Ciraolo E., Gruppi C., Balduini C., et al. Genetic evidence for a predominant role of PI3K{beta} catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 2009, 114:2193-2196.
5. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
6. Christoforidis S., Miaczynska M., Ashman K., Wilm M., Zhao L., Yip S.C., et al. Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat Cell Biol 1999, 1:249-252.
7. Ciraolo E., Iezzi M., Marone R., Marengo S., Curcio C., Costa C., et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci Signal 2008, 1. ra3.
8. Ciraolo E., Morello F., Hobbs R.M., Wolf F., Marone R., Iezzi M., et al. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell 2010, 21:704-711.
9. Crowder R.J., Phommaly C., Tao Y., Hoog J., Luo J., Perou C.M., et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009, 69:3955-3962.
10. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443:651-657.
11. Edgar K.A., Wallin J.J., Berry M., Lee L.B., Prior W.W., Sampath D., et al. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res 2010, 70:1164-1172.
12. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356.
13. Foukas L.C., Berenjeno I.M., Gray A., Khwaja A., Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010, 107:11381-11386.
14. Garcia A., Kim S., Bhavaraju K., Schoenwaelder S.M., Kunapuli S.P. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J 2010, 429:369-377.
15. Gilio K., Munnix I.C., Mangin P., Cosemans J.M., Feijge M.A., van der Meijden P.E., et al. Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. J Biol Chem 2009, 284:33750-33762.
16. Goncalves I., Hughan S.C., Schoenwaelder S.M., Yap C.L., Yuan Y., Jackson S.P. Integrin alpha IIb beta 3-dependent calcium signals regulate platelet-fibrinogen interactions under flow. Involvement of phospholipase C gamma 2. J Biol Chem 2003, 278:34812-34822.
17. Gratacap M.P., Severin S., Chicanne G., Plantavid M., Payrastre B. Different roles of SHIP1 according to the cell context: the example of blood platelets. Adv Enzyme Regul 2008, 48:240-252.
18. Graupera M., Guillermet-Guibert J., Foukas L.C., Phng L.K., Cain R.J., Salpekar A., Pearce W., Meek S., Millan J., Cutillas P.R., et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 2008, 453:662-666.
19. Guillermet-Guibert J., Bjorklof K., Salpekar A., Gonella C., Ramadani F., Bilancio A., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A 2008, 105:8292-8297.
20. Hawkins P.T., Anderson K.E., Davidson K., Stephens L.R. Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006, 34:647-662.
21. Hazeki O., Okada T., Kurosu H., Takasuga S., Suzuki T., Katada T. Activation of PI 3-kinase by G protein betagamma subunits. Life Sci 1998, 62:1555-1559.
22. Heller R., Chang Q., Ehrlich G., Hsieh S.N., Schoenwaelder S.M., Kuhlencordt P.J., et al. Overlapping and distinct roles for PI3K{beta} and {gamma} isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc Res 2008, 80:96-105.
23. Hirsch E., Bosco O., Tropel P., Laffargue M., Calvez R., Altruda F., et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001, 15:2019-2021.
24. Hirsch E., Braccini L., Ciraolo E., Morello F., Perino A. Twice upon a time: PI3K's secret double life exposed. Trends Biochem Sci 2009, 34:244-248.
25. Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005, 11:507-514.
26. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
27. Jia S., Roberts T.M., Zhao J.J. Should individual PI3 kinase isoforms be targeted in cancer?. Curr Opin Cell Biol 2009, 21:199-208.
28. Jiang X., Chen S., Asara J.M., Balk S.P. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010, 285:14980-14989.
29. Kang S., Denley A., Vanhaesebroeck B., Vogt P.K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006, 103:1289-1294.
30. Kasirer-Friede A., Cozzi M.R., Mazzucato M., De Marco L., Ruggeri Z.M., Shattil S.J. Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors. Blood 2004, 103:3403-3411.
31. Kim S., Jin J., Kunapuli S.P. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004, 279:4186-4195.
32. Kim S., Mangin P., Dangelmaier C., Lillian R., Jackson S.P., Daniel J.L., et al. Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets. J Biol Chem 2009, 284:33763-33772.
33. Knight Z.A., Gonzalez B., Feldman M.E., Zunder E.R., Goldenberg D.D., Williams O., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
34. Kovacsovics T.J., Bachelot C., Toker A., Vlahos C.J., Duckworth B., Cantley L.C., et al. Phosphoinositide 3-kinase inhibition spares actin assembly in activating platelets but reverses platelet aggregation. J Biol Chem 1995, 270:11358-11366.
35. Kubo H., Hazeki K., Takasuga S., Hazeki O. Specific role for p85/p110beta in GTP-binding-protein-mediated activation of Akt. Biochem J 2005, 392:607-614.
36. Kurosu H., Katada T. Association of phosphatidylinositol 3-kinase composed of p110beta-catalytic and p85-regulatory subunits with the small GTPase Rab5. J Biochem 2001, 130:73-78.
37. Lee S.H., Poulogiannis G., Pyne S., Jia S., Zou L., Signoretti S., et al. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A 2010, 107:11002-11007.
38. Lemmon M.A. Phosphoinositide recognition domains. Traffic 2003, 4:201-213.
39. Li Z., Zhang G., Feil R., Han J., Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3. Blood 2006, 107:965-972.
40. Maier U., Babich A., Nurnberg B. Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J Biol Chem 1999, 274:29311-29317.
41. Marques M., Kumar A., Cortes I., Gonzalez-Garcia A., Hernandez C., Moreno-Ortiz M.C., et al. Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase. Mol Cell Biol 2008, 28:2803-2814.
42. Martin V., Guillermet-Guibert J., Chicanne G., Cabou C., Jandrot-Perrus M., Plantavid M., et al. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010, 115:2008-2013.
43. Maxwell M.J., Yuan Y., Anderson K.E., Hibbs M.L., Salem H.H., Jackson S.P. SHIP1 and Lyn kinase negatively regulate integrin alpha IIb beta 3 signaling in platelets. J Biol Chem 2004, 279:32196-32204.
44. McCrea H.J., De Camilli P. Mutations in phosphoinositide metabolizing enzymes and human disease. Physiology (Bethesda) 2009, 24:8-16.
45. Munday A.D., Berndt M.C., Mitchell C.A. Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood 2000, 96:577-584.
46. Nieswandt B., Varga-Szabo D., Elvers M. Integrins in platelet activation. J Thromb Haemost 2009, 7(Suppl. 1):206-209.
47. Pasquet J.M., Bobe R., Gross B., Gratacap M.P., Tomlinson M.G., Payrastre B., et al. A collagen-related peptide regulates phospholipase Cgamma2 via phosphatidylinositol 3-kinase in human platelets. Biochem J 1999, 342(Pt 1):171-177.
48. Payrastre B., Missy K., Giuriato S., Bodin S., Plantavid M., Gratacap M. Phosphoinositides: key players in cell signalling, in time and space. Cell Signal 2001, 13:377-387.
49. Pendaries C., Tronchere H., Plantavid M., Payrastre B. Phosphoinositide signaling disorders in human diseases. FEBS Lett 2003, 546:25-31.
50. Ragab A., Severin S., Gratacap M.P., Aguado E., Malissen M., Jandrot-Perrus M., et al. Roles of the C-terminal tyrosine residues of LAT in GPVI-induced platelet activation: insights into the mechanism of PLC gamma 2 activation. Blood 2007, 110:2466-2474.
51. Rameh L.E., Cantley L.C. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 1999, 274:8347-8350.
52. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
53. Sasaki J., Kofuji S., Itoh R., Momiyama T., Takayama K., Murakami H., et al. The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death. Nature 2010, 465:497-501.
54. Sasaki T., Takasuga S., Sasaki J., Kofuji S., Eguchi S., Yamazaki M., et al. Mammalian phosphoinositide kinases and phosphatases. Prog Lipid Res 2009, 48:307-343.
55. Schoenwaelder S.M., Ono A., Nesbitt W.S., Lim J., Jarman K., Jackson S.P. Phosphoinositide 3-kinase p110 beta regulates integrin alpha IIb beta 3 avidity and the cellular transmission of contractile forces. J Biol Chem 2010, 285:2886-2896.
56. Stojanovic A., Marjanovic J.A., Brovkovych V.M., Peng X., Hay N., Skidgel R.A., et al. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Biol Chem 2006, 281:16333-16339.
57. Tang X., Downes C.P. Purification and characterization of Gbetagamma-responsive phosphoinositide 3-kinases from pig platelet cytosol. J Biol Chem 1997, 272:14193-14199.
58. Toker A. Phosphoinositides and signal transduction. Cell Mol Life Sci 2002, 59:761-779.
59. Torbett N.E., Luna-Moran A., Knight Z.A., Houk A., Moasser M., Weiss W., et al. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J 2008, 415:97-110.
60. Trumel C., Payrastre B., Plantavid M., Hechler B., Viala C., Presek P., et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999, 94:4156-4165.
61. van der Meijden P.E., Schoenwaelder S.M., Feijge M.A., Cosemans J.M., Munnix I.C., Wetzker R., et al. Dual P2Y 12 receptor signaling in thrombin-stimulated platelets-involvement of phosphoinositide 3-kinase beta but not gamma isoform in Ca2+ mobilization and procoagulant activity. FEBS J 2008, 275:371-385.
62. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
63. Vanhaesebroeck B., Leevers S.J., Ahmadi K., Timms J., Katso R., Driscoll P.C., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001, 70:535-602.
64. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009, 69:4286-4293.
65. Wu Y., Asazuma N., Satoh K., Yatomi Y., Takafuta T., Berndt M.C., et al. Interaction between von Willebrand factor and glycoprotein Ib activates Src kinase in human platelets: role of phosphoinositide 3-kinase. Blood 2003, 101:3469-3476.
66. Yap C.L., Anderson K.E., Hughan S.C., Dopheide S.M., Salem H.H., Jackson S.P. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin alpha(IIb)beta(3). Blood 2002, 99:151-158.
67. Yin H., Stojanovic A., Hay N., Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 2008, 111:658-665.
68. Zhu Q., Youn H., Tang J., Tawfik O., Dennis K., Terranova P.F., et al. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008, 27:4569-4579.